Reuters logo
BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene
2017年3月16日 / 上午11点28分 / 6 个月前

BRIEF-Oncolytics Biotech enters collaboration with Myeloma UK and Celgene

March 16 (Reuters) - Oncolytics Biotech Inc

* Oncolytics biotech enters into first-in-class collaboration with Myeloma UK and Celgene using Reolysin in combination with Imnovid or Revlimid in patients with Myeloma

* Phase 1b trial will study immuno-viral therapy, Reolysin in combination with Celgene Corporation’s immunomodulatory drugs Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below